Bolt Biotherapeutics

Yahoo Finance • 8 days ago

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Bioth... Full story

Yahoo Finance • 2 months ago

Bolt Biotherapeutics GAAP EPS of -$4.46 beats by $1.99, revenue of $1.8M beats by $0.98M

* Bolt Biotherapeutics press release [https://seekingalpha.com/pr/20201891-bolt-biotherapeutics-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:BOLT [https://seekingalpha.com/symbol/BOLT]): Q2 GAAP EPS of -$4... Full story

Yahoo Finance • 2 months ago

Bolt Revenue Jumps 39 Percent in Q2

Key Points Revenue grew 38.5% year over year (GAAP basis) in Q2 2025 and was more than double analyst expectations, with GAAP revenue of $1.80 million exceeding the analyst estimate of $0.82 million by 120.1%. Loss per share (GAAP) improv... Full story

Yahoo Finance • 2 months ago

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -... Full story

Yahoo Finance • 2 months ago

E-Hailing Market Competitive Landscape and Company Profiles Report 2025 | E-Hailing Market Forecast to Hit $170.11 Billion by 2029

Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "E-Hailing Market Report 2025" has been added to ResearchAndMarkets.com's offering. The e-hailing market size has grown rapidly in recent years. It will grow from $67.65 billion in 2024 t... Full story

Yahoo Finance • 5 months ago

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundament... Full story

Yahoo Finance • 7 months ago

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will present data f... Full story

Yahoo Finance • 7 months ago

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025BDC-3042 Phase 1 clinical trial fully enrolled the highest dose cohort with no dose-limiting toxicities (DLTs), results will be reported in second quarter... Full story

Yahoo Finance • 2 years ago

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

Bolt Biotherapeutics, Inc. BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancers Poster detailing trial design and ratio... Full story

Yahoo Finance • 2 years ago

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

BDC-1001 program advances in multiple Phase 2 clinical studies in patients with HER2-positive colorectal, gastric, endometrial, and metastatic breast cancer, with recent updated data at ESMO showing improved clinical efficacy and longer du... Full story

Yahoo Finance • 2 years ago

Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference

REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will pa... Full story

Yahoo Finance • 2 years ago

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D) Improved efficacy with one partial response (PR) improving to a complete response (CR), two additional patients with long-term stable disease... Full story

Yahoo Finance • 2 years ago

Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting

Company to debut preclinical data illustrating how the combination of trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumabCompany announces Claudin 18.2 ISAC pr... Full story

Yahoo Finance • 2 years ago

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid tumors REDWOOD CITY, Calif., Oct. 17, 2... Full story

Yahoo Finance • 2 years ago

Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

REDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer, today announced that... Full story

Yahoo Finance • 2 years ago

Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersThe FDA granted BDC-1001 Orphan Drug Designation for the treatment o... Full story

Yahoo Finance • 2 years ago

Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042

REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, announced today the issuance of... Full story

Yahoo Finance • 2 years ago

Bolt Biotherapeutics to Participate in September Investor Conferences

REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will p... Full story

Yahoo Finance • 2 years ago

Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

REDWOOD CITY, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer, today announced tha... Full story

Yahoo Finance • 3 years ago

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Positive topline data from BDC-1001 dose-escalation clinical study validates the ability of the Boltbody™ ISAC platform to generate anti-tumor activity with acceptable safetyBDC-1001 advances into a focused Phase 2 program commencing in 20... Full story